Mednax, Inc (NYSE:MD) has been given a consensus rating of “Hold” by the fifteen analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $64.50.
Several research firms have commented on MD. Jefferies Group LLC reissued a “hold” rating on shares of Mednax in a research note on Monday, April 10th. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research note on Thursday, April 13th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a research note on Thursday, May 4th. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $55.00 to $68.00 in a research note on Thursday, June 22nd.
In other news, Director Manuel Kadre bought 21,704 shares of the firm’s stock in a transaction on Friday, May 5th. The stock was bought at an average cost of $55.79 per share, for a total transaction of $1,210,866.16. Following the completion of the acquisition, the director now directly owns 111,255 shares in the company, valued at approximately $6,206,916.45. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the completion of the transaction, the insider now owns 296,379 shares of the company’s stock, valued at $16,300,845. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,074 shares of company stock valued at $1,830,508. Corporate insiders own 2.40% of the company’s stock.
Several hedge funds have recently bought and sold shares of MD. Ladenburg Thalmann Financial Services Inc. boosted its stake in Mednax by 5.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $106,000 after buying an additional 77 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Mednax by 9.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 15,780 shares of the company’s stock valued at $1,052,000 after buying an additional 1,360 shares in the last quarter. Norges Bank bought a new stake in Mednax during the fourth quarter valued at approximately $56,794,000. Gulf International Bank UK Ltd boosted its stake in Mednax by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 30,620 shares of the company’s stock valued at $2,124,000 after buying an additional 450 shares in the last quarter. Finally, Fenimore Asset Management Inc. boosted its stake in Mednax by 7.3% in the first quarter. Fenimore Asset Management Inc. now owns 858,880 shares of the company’s stock valued at $59,589,000 after buying an additional 58,070 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: This article was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://transcriptdaily.com/2017/07/23/mednax-inc-nysemd-receives-64-50-consensus-target-price-from-analysts.html.
Mednax (NYSE MD) traded up 0.87% during mid-day trading on Monday, reaching $58.11. 456,331 shares of the company were exchanged. The stock has a market capitalization of $5.37 billion, a P/E ratio of 17.35 and a beta of 0.44. Mednax has a 12 month low of $53.80 and a 12 month high of $76.04. The company’s 50 day moving average price is $57.74 and its 200-day moving average price is $63.76.
Mednax (NYSE:MD) last released its earnings results on Thursday, May 4th. The company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.01. The firm had revenue of $835.60 million for the quarter, compared to analysts’ expectations of $837.01 million. Mednax had a net margin of 9.54% and a return on equity of 12.81%. Mednax’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the company earned $0.87 EPS. On average, equities analysts expect that Mednax will post $3.58 earnings per share for the current fiscal year.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.